For patients with locally advanced or metastatic penile cancer (la/mPC), platinum-based combination chemotherapy remains the standard of care (SOC), yet treatment options are limited, and prognosis remains poor. Programmed cell death ligand 1 (PD-L1) is upregulated in 40% to 60% of cases, highlighting the potential for immunotherapy in la/mPC. Cemiplimab, a programmed cell death 1 (PD-1) inhibitor, is currently approved for locally advanced or metastatic cutaneous squamous cell carcinoma. At the American Society of Clinical Oncology 2025 Genitourinary ...
Testicular, Penile, and Rare Malignancies
Advertisement
Latest News
Specificity findings varied, but some studies suggested similar or slightly higher rates in favor of MRI.
There is a lack of data on 1L regimens for distant metastatic PSCC, with a 2-year OS rate of just 21%.
Drs. Necchi and Tawagi highlight some the challenges in penile cancer, including "suboptimal" neoadjuvant, adjuvant options.
Paclitaxel, ifosfamide, and cisplatin is a combination commonly used for the treatment of germ cell tumors.
A recent dose-escalation study has demonstrated the safety and efficacy of cabo/nivo or cabo/nivo/ipi for several GU cancers.
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Advertisement
Advertisement
Latest News
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.